Robert B. Chambers

Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents

OBJECTIVE This study aimed to report three patients with hemorrhagic ocular and orbital complications associated with the use of systemic thrombolytic agents. DESIGN The study design was a retrospective small case series. PARTICIPANTS Three eyes of three patients were studied. INTERVENTION Surgical procedures to reduce intraocular pressure or relieve optic nerve compression were performed. MAIN OUTCOME MEASURES Visual acuity and intraocular pressure were measured. RESULTS Three patients received an intravenous thrombolytic agent on diagnosis of an acute myocardial infarction. One patient had a spontaneous suprachoroidal hemorrhage develop with secondary acute angle closure glaucoma shortly after receiving tissue plasminogen activator. Another patient had an orbital hemorrhage develop on receiving tissue plasminogen activator 4 days after an uncomplicated cataract extraction. The third patient experienced an orbital hemorrhage while receiving streptokinase 1 day after undergoing an external levator resection. Two patients suffered significant visual loss due to glaucoma or compressive optic neuropathy. CONCLUSIONS The onset of eye pain or visual loss after the administration of a systemic thrombolytic agent should alert the physician to the possibility of an ocular or adnexal hemorrhage. Prompt diagnosis and treatment can improve the likelihood of a favorable visual outcome.

Ocular Toxicity Of Vitreal Pluronic Polyol F-127

To evaluate pluronic polyol F-127 (PF-127) as a vitreous substitute and an intraocular drug delivery system, a total vitrectomy was performed on 18 New Zealand rabbits (18 eyes). The vitreous was replaced with either PF-127 (9 eyes) or balanced salt solution (9 eyes). There was little difference clinically between the eyes containing PF-127 and the control eyes. Both groups showed mild postoperative inflammation, with no differences in intraocular pressures. Histopathologic findings for the control group showed no significant retinal alteration, and serial ERG findings were within normal limits. In contrast, the eyes containing PF-127 showed marked destruction of the retina by 2 weeks after surgery. The ERG amplitudes decreased dramatically to a flat tracing by 24 hours after surgery. Although it is attractive as a potential vitreous substitute, PF-127 is not safe for human use, at least at the concentration used.

Bungee cord-associated ocular injuries

PURPOSE To report ocular injuries associated with the use of bungee cords. METHOD Four patients with bungee cord-associated ocular trauma are presented. RESULTS Four eyes of four patients demonstrated severe contusion injuries associated with bungee cord trauma. Ocular injuries in the four eyes included a variable combination of corneal abrasion, hyphema, iridodialysis, anterior chamber angle recession, secondary glaucoma, lens subluxation, vitreous hemorrhage, and retinal detachment. Three of the four eyes required ophthalmic surgery. All eyes had anterior chamber angle recession and required continuing ophthalmic care. CONCLUSION Bungee cords may be associated with severe ocular injury and should be used with caution.

Systemic immunostimulation after retinal laser treatment in retinitis pigmentosa

Systemic immunostimulation followed an experimental treatment trial of scatter argon laser photocoagulation directed to the retina of one eye of 10 patients with heredo-degenerative retinitis pigmentosa (RP). Significantly increased RP lymphocyte CD25, CD26, and CD4/CD26 activation epitope expressions over prelaser values and controls were found with a normalization of soluble interleukin-2 receptor secretion after laser treatment. Serum interferon-gamma was low both pre- and postlaser. Interestingly, when a panel of viral antibodies was tested, only those to rubella virus were elevated in the early postlaser period. The character of RP immunostimulation after laser-induced inflammation could be consistent with an antigenic stimulus from laser-released retinal proteins which might be of autoimmune or latent infectious origin. Enhanced immune responses may be a common but unrecognized sequellae of retinal laser.

Modified vitrectomy for impending macular holes

We report a consecutive series of 13 eyes (11 patients) treated with pars plana vitrectomy, in which surgical manipulation of the prefoveal layer of cortical vitreous was avoided, for stage I (eight eyes) and stage II (five eyes) macular hole formation. Average follow up was 8.1 months (range, 2 to 13 months). There was no significant improvement in vision in the patients with stage II macular holes; however, vision in these patients stabilized and did not fall below 20/400. Visual acuity improved in seven of the eight patients with stage I holes. The results for both these groups achieved by our modified vitrectomy, which is relatively easy to perform and involves minimal intraoperative manipulation of the fovea, are consistent with those obtained by methods involving more aggressive cortical vitreous stripping of the fovea.